VYNE Therapeutics Inc.

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immunological (I&I) conditions with high unmet need. Led by a proven and resourceful team of drug developers, VYNE is applying scientific innovation to advance novel therapies that have the potential to improve the lives of millions of people afflicted by autoimmune diseases. The catalyst of the company’s differentiated approach is its proprietary InhiBET™ Platform that potentially unlocks a promising new drug target for improving the treatment of challenging I&I diseases with significant unmet medical needs. BETs are a family of proteins that are believed to play a causal role in the regulation of inflammatory genes that are implicated in numerous diseases. VYNE has done the first formative work in applying BET inhibition to the treatment of autoimmune disease. The company’s leadership is demonstrated in clinical development, where VYNE is building a superior body of evidence that informs the advancement of its two lead product candidates: VYN201 for the treatment of vitiligo; and VYN202, a highly potent and selective BET inhibitor that offers promise across a broad array of chronic autoimmune indications. To learn more about us and our pipeline, visit vynetherapeutics.com. Read our Social Media Guidelines here: https://vynetherapeutics.com/social-media-guidelines/.